When considering single-dose preparations, it is fundamental that the patient receives in his individual dose an amount of drug close to that claimed on the label. Since drug content and content uniformity of single-dose preparations depend on a number of processes associated with their manufacture, it is obviously unrealistic to expect every unit of product to possess exactly the same amount of the active ingredient. For that reason, pharmacopeial standards and specifi cations have been established to provide limits for permissible variations in the amount of active ingredient of individual single-dose units. Th e aim of our study was to determine the applicability of content uniformity and dissolution variation test on ropinirole hydrochloride tablets. According to the results obtained, we may conclude that analyzed ropinirole hydrochloride tablets satisfi ed pharmacopeial requirements concerning content uniformity and dissolution testing. In this case RSD tended to increase with the decrease of the labeled strength. It is obvious from the R  value, as well. On the other side, if consider larger number of lots, analyzed by diff erent assay methods and various sample preparation procedures this correlation is less pronounced. Th is may be a consequence of diff erent assay techniques applied, HPLC, UV-D or UV.
Introduction
When considering single-dose preparations, it is fundamental that the patient receives in his individual dose an amount of drug close to that claimed on the label. Since drug content and content uniformity of single-dose preparations depend on a number of processes associated with their manufacture, it is obviously unrealistic to expect every unit of product to possess exactly the same amount of the active ingredient. For that reason, pharmacopeial standards and specifications have been established to provide limits for permissible variations in the amount of active ingredient of individual single-dose units () . Content uniformity is one in a series of tests in a therapeutic product specifi cation that assesses the quality of a batch. Testing for content uniformity helps ensure that the strength of a therapeutic product remains within specified acceptance limits. Recent national and international regulatory and compendial efforts have focused on harmonizing content uniformity testing, with several different approaches under consideration. Th e diff ering approaches arise from diff ering motivations (batch release vs. marketplace testing of a single unit), testing (uniformity of content vs. uniformity of mass), products covered (oral, oral inhalation and nasal drug products), and statistical strategies () . The subject of content uniformity of single-dose units has been considered a lot. However, different methodologies and specifications are still prescribed in different official pharmacopeias like of European Pharmacopeia  th (Eur. Pharm.  th ) () and United States Pharmacopeia  st (USP ) () . Characterization studies conducted during product development assess safety, effi cacy, and quality measures for a therapeutic product. For therapeutic products approved through a regulatory process, safety and effi cacy characterization studies are refl ected in the approved product label. Quality characterization studies are performed in relation to safety and efficacy studies and are at times associated with specified acceptance criteria. For example, product bioavailability and bioequivalence quality studies are one-time product performance characterization studies that, in the case of bioequivalence, may be assessed using specifi ed criteria and pre-determined pass/fail bioequivalence limits (,) . Quality characterization studies provide specifi cations, defi ned as a list of tests, references to analytical procedures to evaluate those tests, and appropriate acceptance criteria (). Th e aim of our study was to: -compare content uniformity and dissolution variation test of diff erent tablets, labeled strength ,; ,; ;  and  mg, respectively (diff erent assay techniques applied, HPLC, UV-D or UV). -study the applicability of content uniformity and dissolution variation test of ropinirole hydrochloride tablets, labeled strength ,; ,; ;  and  mg, respectively (HPLC assay techniques applied).
Current approaches to content uniformity data analysis
Current approaches to content uniformity testing are based on either parametric tolerance intervals or a nonparametric procedure that can be recognized as a nonparametric tolerance interval. Three decisions are needed to assess content uniformity using a tolerance interval approach () . These are: -acceptable tolerance limits (e.g., - of label claim); -minimum proportion, p, of the batch that should fall within the limits (e.g.,  of units in a batch); and -degree of confi dence needed to make an accept/reject decision (e.g., ).  and ) . For all combinations of means and standard deviations on or below each curve, at least  of the distribution falls within the tolerance limits ( Figure ) . Th e upper curve is for wide tolerance limits, - of label claim, and thus allows more combinations of means and variances. The lowest curve, with narrow specified tolerance limits of -, is more restrictive. For all combinations of means and standard deviations on or below each curve, at least a specifi ed portion of the distribution falls within the tolerance limits of - ( Figure ) . Th e lowest curve is a high coverage probability of  and thus allows fewer combinations of means and variances. The upper curve, with lower coverage probability is less restrictive. For parametric tolerance interval testing, the general form of the criterion is Y ±kS, where S is the observed standard deviation, and k is a tolerance interval constant that accounts for sample size as well as the population fraction p () . For this application, Y is the diff erence between a test mean, X , and a reference mean. Th e reference mean in content uniformity may be fi xed as either the label claim or rubric mean, M, expressed as a percent. Th e rubric mean can sometimes be greater or less than  of label claim, with corresponding changes in tolerance limits. After subtracting the reference mean the tolerance limits are similarly adjusted, e.g., - of label claim becomes ±. When the tolerance limits are symmetric about zero, as ±, the decision to accept the batch can be made using the largest absolute value from the interval; that is, reducing the tolerance interval to a single value, |Y |+ kS. Usually, parametric tolerance interval approaches assume normal distribution of the data, possibly following a transformation, such as to log scale. Nonparametric approaches do not assume normal distribution of test data. If the normality assumption is correct (and normality seems reasonable for content uniformity testing), the parametric tolerance interval approach ought to make better use of the data than approaches based on counts of values falling within specifi ed intervals () . All current content uniformity tests, whether non-parametric or parametric, use a two tier approach with fi xed numbers of units allowed for testing in each tier. If results are suffi ciently positive in the fi rst stage (tier) of testing, then the study stops. If insuffi ciently positive, the study may continue to the second stage. In the language of clinical trials, the initial tiers of multiple-tier testing are interim analyses. When two tiers are used, the calculation of the actual type I (false positive) error rate for the full two-tier design needs to take into account both tiers. For example, a  test at each tier will have a combined type I error rate exceeding  () . For nonparametric tolerance intervals, the method of Simon () can be adopted for two-tier designs. Hauck and Shaikh () developed a method for parametric tolerance intervals and designs of one or more tiers.
Current approaches for dissolution testing data analysis
Acceptance criteria for the dissolution procedure can either be a limit (the Q value) or a range (upper and lower percent dissolved at a specifi ed time). Although acceptance criteria may be based on an in vitro-in vivo correlation () , setting acceptance criteria frequently lacks a formal approach for most dosage forms (). USP and other pharmacopeas currently mostly use nonparametric approach for both content uniformity and dissolution testing. For content uniformity testing, Katori et al. () proposed replacing the current USP approach (test by attributes) with a parametric approach (test by variables), using a tolerance interval () .
Moving from a nonparametric to a parametric approach depends in part on whether a specifi c distribution, such as the normal, can be assumed. Th e normal distribution can be a reasonable assumption for content uniformity testing but not necessarily for dissolution testing. Normal distribution of dissolution data may be unlikely due to the boundary of  dissolved-with values sometimes greater than  given variability in assay and content. Th e  boundary forces non-symmetry and hence non-normality of distribution. Although data transformation may help, one solution to this issue would be to choose the time at which dissolution is measured to achieve values that are acceptably below . In contrast to use of a parametric tolerance interval approach for content uniformity testing, Katori et al. () proposed a parametric confidence interval approach for dissolution testing ( () ; for example, at least  of dissolution values for a product fall within a specifi ed range with some specified level of confidence. A choice between the two approaches is based on what quantity (or quantities) best characterizes the distribution for the problem of interest. Characterizing the distribution solely by the mean and its confidence interval is insufficientthey are essentially uninformative as to the width of the distribution. In order to consider variability as well, standard deviation controls could be established.
Materials and Methods

Materials
For this study, ropinirole hydrochloride tablets were used; labels claim ,; ,; ;  and  mg, respectively.
Methods
Content uniformity analysis
For each individual lot,  units were sampled. Measurements were done by the individual manufacturer. The assay methods used were HPLC and UV absorption. Th e mean and SD of drug content, formulation weight and concentration of active ingredient (w/w) were calculated for each group of  units in a single lot.
Units were weighed and assayed in succession.
The concentration of the active ingredient was calculated by dividing drug content by formulation weight that included the weight of coating.
Dissolution profi le analysis For each individual lot,  units were sampled. Dissolution samples were collected for analysis and re- placed with an equal volume of fresh dissolution fluid to maintain a constant total volume. The assay methods used were HPLC and UV absorption.
Results and Discussion
The content and dissolution testing values are accessible only through chemical analysis subject to measurement errors. As the purpose is to calculate tolerance interval for the true active content, the standard deviation and relative standard deviation should stand for the variability of the dosage units. In the measurements, however, there are two sources of variation: variability of the dosage units (non-homogeneity) and the measurement (analytical) error.
Relationship between labeled strength and content uniformity
The results of our content uniformity analysis of different tablets ( lots), labeled strength ,; ,; ;  and  mg are summarized in Table  and Figure  . Th e results of content uniformity analysis of ropinirole hydrochloride tablets ( lot,  diff erent label strengths, HPLC assay method) are summarized in Table  and Figure  .
Relationship between labeled strength and percent of drug dissolved
Th e results of our dissolution test analysis of ropinirole hydrochloride tablets ( lots) are summarized in Table   and Figure  . Th e results for dissolution testing of ropinirole hydrochloride tablets ( lot,  diff erent label strengths, HPLC assay method) are summarized in Table  and Figure  .
Th e content uniformity and dissolution testing of a formulation is represented by intra-lot variation (RSD). In this case RSD tended to increase with the decrease of the labeled strength. It is obvious from the R  value, as well. On the other side, if we take into consideration larger number of lots, analyzed by diff erent assay methods and diff erent sample preparation procedures this correlation is less pronounced. Th is can be the consequence of different assay techniques applied, HPLC, UV-D or UV. 
Conclusion
◊ According to the results obtained, we may conclude that the analyzed ropinirole hydrochloride tablets from satisfi ed pharmacopeial requirements concerning content uniformity and dissolution testing ◊ In this case, RSD tended to increase with the decrease of the labeled strength. It is obvious from the R  value, as well. ◊ On the other side, if we take into consideration larger number of lots, analyzed by diff erent assay methods and different sample preparation procedures this correlation is less pronounced. Th is can be the consequence of diff erent assay techniques applied, HPLC, UV-D or UV.
